香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 修訂《公司章程》 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據香港聯合交易所有限 公司證券上市規則第13.51(1)條而作出。 茲提述本公司於2024年5月29日召開之2023年度股東週年大會、2024年第一次A 股類別股東大會及2024年第一次H股類別股東大會審議通過的關於授予本公司董 事會（「董事會」）回購H股的一般性授權的議案（「2024年回購授權」）。根據2024年 回購授權，本公司於自2024年6月27日至本公告日的期間共計回購2,629,100股H 股，其中2,296,200股H股已完成註銷。 上述2,296,200 股H股註銷完成後，本公司股份總數由 235,489,895 股變更 為 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥618,542,128.87, a decrease of 4.25% compared to ¥645,995,271.22 in the same period last year[4] - The net profit attributable to shareholders was ¥90,312,072.67, down 7.41% from ¥97,541,532.98 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥88,474,729.61, reflecting a decrease of 7.08% compared to ¥95,217,851.02 in the previous year[4] - Total revenue for Q1 2025 was ¥618.54 million, a decrease of 4.9% compared to ¥645.99 million in Q1 2024[16] - Net profit for Q1 2025 was ¥83.81 million, a decline of 9.4% from ¥92.49 million in Q1 2024[16] - Basic earnings per share for Q1 2025 were ¥0.39, compared to ¥0.42 in Q1 2024[17] Cash Flow - The net cash flow from operating activities increased by 13.04% to ¥85,876,398.75, compared to ¥75,969,702.64 in the same period last year[4] - In Q1 2025, the net cash flow from operating activities was ¥85,876,398.75, an increase of 13.5% compared to ¥75,969,702.64 in Q1 2024[19] - Total cash inflow from operating activities was ¥640,948,930.38, down 9.1% from ¥705,232,753.89 in the previous year[19] - The net cash flow from investing activities was -¥179,294,387.16, a significant decrease from ¥159,290,447.77 in Q1 2024[19] - The net cash flow from financing activities was -¥79,079,486.98, compared to a positive cash flow of ¥42,137,675.19 in Q1 2024[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,127,388,076.14, a slight increase of 0.08% from ¥7,121,392,176.35 at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to ¥7.13 billion, slightly up from ¥7.12 billion at the end of 2024[14] - Total liabilities decreased to ¥1.18 billion as of March 31, 2025, from ¥1.20 billion at the end of 2024[14] - The company’s total equity increased to ¥5.95 billion as of March 31, 2025, from ¥5.92 billion at the end of 2024[14] Research and Development - Research and development expenses totaled ¥48,418,019.42, a decrease of 25.40% from ¥64,900,123.30 year-on-year[4] - Research and development expenses for Q1 2025 were ¥48.42 million, a decrease of 25.5% from ¥64.90 million in Q1 2024[16] - The proportion of R&D expenses to operating revenue was 7.83%, down from 10.05% in the previous year, a reduction of 2.22 percentage points[4] Inventory and Cash Equivalents - The company reported an increase in inventory to ¥488.20 million as of March 31, 2025, compared to ¥490.65 million at the end of 2024[13] - Cash and cash equivalents were ¥2.54 billion as of March 31, 2025, down from ¥2.63 billion at the end of 2024[13] - The total cash and cash equivalents at the end of Q1 2025 were ¥944,673,243.30, an increase from ¥846,192,318.84 in Q1 2024[20] Non-Recurring Gains - The company reported non-recurring gains of ¥1,837,343.06 for the period, primarily from government subsidies and asset disposals[7]

環境，社會 與管治報告 2024 | 目錄 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 關於本報告 | 2 | 關於本公司 | 4 | | | | | | 年度主要榮譽及績效亮點 | 5 | | | | | | | | 管理 | ESG | | | | | | | | 治理架構 | ESG | 8 | | | | | | | 01 | | | | | | | | | 董事會聲明 | 8 | 利益相關方溝通 | 9 | | | | | | 雙重重要性評估 | 10 | | | | | | | | 合規運營 | | | | | | | | | 風險管理與內部控制 | 13 | | | | | | | | 02 | | | | | | | | | 商業道德 | 14 | 信息安全與隱私保護 | 16 | | | | | | 科技倫理 | 17 | | | | | | | | 產品與創新 | | | | | | | | | 研發創新 | 19 | 03 | 知識產權保護 | 24 | | | | | 供應鏈安全 | 25 | ...

Financial Performance - The company reported a revenue of RMB 2,679.67 million for 2024, an increase of RMB 44.76 million, representing a growth of 1.70% compared to the previous year[10]. - Net profit attributable to shareholders was approximately RMB 420.45 million, remaining stable compared to the previous year[10]. - Gross profit for 2024 was RMB 1,868.79 million, with a gross margin of 69.7%[9]. - The company’s net profit margin was 15.6%, slightly down from 15.7% in the previous year[9]. - The company’s basic earnings per share for 2024 was RMB 1.80, compared to RMB 1.75 in 2023[9]. - The overall revenue for the company in the reporting period was approximately RMB 2,679.67 million, an increase of RMB 44.76 million or 1.70% from RMB 2,634.91 million in 2023[59]. - The company's gross profit margin for the reporting period was 69.74%, a slight decrease of 0.60 percentage points from 70.34% in 2023[61]. - Other income and gains for the reporting period amounted to approximately RMB 149.76 million, an increase of about RMB 15.47 million or 11.52% compared to RMB 134.29 million in 2023, primarily due to the recognition of performance compensation from minority shareholders of a subsidiary[62]. Research and Development - Research and development expenses amounted to RMB 238.93 million, an increase of RMB 18.83 million, reflecting a growth of about 8.56% and accounting for 8.92% of total revenue[11]. - R&D expenses for the reporting period were approximately RMB 238.93 million, an increase of about RMB 18.83 million or 8.56% from RMB 220.10 million in 2023, reflecting the company's ongoing investment in expanding its ophthalmology and medical aesthetics product lines[63]. - The company is actively developing advanced artificial lens products, including hydrophobic and hydrophilic extended depth of focus lenses, with clinical trials expected to begin in July 2024[39]. - The company is advancing its research on hydrophilic aspheric multifocal intraocular lenses, with clinical trials completed and registration expected in early 2025[42]. Product Development and Market Expansion - The company successfully launched the globally first organic cross-linked hyaluronic acid product "Hai Mei Yue Bai" in July 2024, and sodium hyaluronate eye drops were approved in March 2024[11]. - The company is expanding its product lines in aesthetic medicine and ophthalmology, with several key projects in clinical trials, including high oxygen permeability scleral lenses[11]. - The group’s hyaluronic acid product line achieved revenue of RMB 737.86 million in 2024, an increase of RMB 138.45 million, representing a growth rate of 23.10% compared to the previous year[28]. - The total revenue from medical beauty and wound care products reached RMB 1,189.22 million, up RMB 136.42 million, with a growth rate of approximately 12.96%[22]. - The company plans to expand the application of hEGF products into various medical fields, including pediatrics and oncology, beyond traditional uses[28]. - The company plans to focus on four rapidly developing treatment areas: medical beauty, wound care, ophthalmology, and orthopedics, emphasizing research and innovation[54]. Market Trends and Competitive Position - The market for non-surgical beauty treatments in China is expected to grow by about 10% in 2024, with a projected compound annual growth rate of 10-15% over the next four years[26]. - The Chinese medical beauty market size grew from RMB 99.3 billion in 2017 to RMB 189.2 billion in 2021, with a compound annual growth rate of 17.5%[24]. - The penetration rate of medical beauty treatments in China is significantly lower than in Brazil, the US, and South Korea, indicating potential for future market growth[24]. - The company achieved a market share increase in the orthopedic sector, rising from 46.54% in 2022 to 50.44% in 2023, solidifying its position as the leading manufacturer of viscoelastic supplements for joint injections in China[46]. Financial Management and Shareholder Returns - The company distributed a total of RMB 166,956,729.00 as final dividends and increased share capital by 66,782,692 shares by the end of July 2024[13]. - For the first half of 2024, the company distributed interim dividends totaling RMB 92,902,248.40[13]. - The board proposed a final dividend of RMB 0.6 per share (before tax) for the year ending December 31, 2024, totaling RMB 138,023,048.4 (before tax) based on the total issued shares of 233,193,695, after accounting for treasury shares[89]. - The company has adopted a dividend policy that emphasizes a balance between reasonable returns to investors and sustainable development[97]. - The company aims for a minimum cash dividend proportion of 80% for mature stages without significant capital expenditure[98]. Regulatory and Compliance - The company emphasizes the importance of environmental protection and has established and continuously improved its environmental management systems, ensuring compliance with pollution discharge standards[85]. - The company has not encountered any significant violations of environmental laws and regulations during the reporting period[85]. - The company has complied with all applicable provisions of the corporate governance code under the Hong Kong Listing Rules during the reporting period[186]. - There are no significant legal proceedings or arbitrations involving the company during the reporting period[187]. Employee and Management Structure - The company had approximately 2,156 employees as of December 31, 2024, with total employee compensation amounting to approximately RMB 692.94 million, an increase of about RMB 62.86 million from the previous year[70]. - The company’s employee compensation policy aims to enhance governance structure and motivate core teams to improve competitiveness[145]. - Non-executive directors receive fixed remuneration based on their background, experience, and responsibilities, with no additional director remuneration for executive directors[144]. Share Repurchase and Capital Management - The company repurchased 1,418,934 A-shares, accounting for 0.61% of total shares, with a total transaction amount of approximately RMB 106.27 million[13]. - A total of 2,492,100 H-shares were repurchased during the year, with a total expenditure of HKD 75,709,045.00[120]. - The board believes that the share repurchase enhances investor confidence and aligns the interests of shareholders, the company, and employees[121]. Governance and Stakeholder Engagement - The company maintains good relationships with stakeholders, including customers, shareholders, government agencies, employees, suppliers, and the community, to achieve medium- and long-term goals[86]. - The company has established a governance structure consisting of the general meeting of shareholders, the board of directors, the supervisory board, and the management team[195].

Shanghai Haohai Biological Technology Co., Ltd. 上海昊海生物科技股份有限公司 (a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock code 股份代號： 6826) 28 April 2025 Dear registered shareholder(s), Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter dated 24 January 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Shanghai Haohai Biologi ...

Shanghai Haohai Biological Technology Co., Ltd. 上海昊海生物科技股份有限公司 (a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock code 股份代號： 6826) Dear non-registered shareholder(s), 28 April 2025 Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter dated 24 January 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Shanghai Haohai Bio ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | A 股（上海證券交易所科創板，股份代號：688366） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於變更持續督導保薦代表人的公告》，僅供參考。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 中國上海，2025年4月11日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海昊海生物科技股份有限公司（以下简称"公司"）于近日收到瑞银证券 有限责任公司（以下简称"瑞银证券"）出具的《瑞银证券有限责任公司关于 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 主席 侯永泰 中國上海，二零二五年四月十一日 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 董事會會議召開日期 上海昊海生物科技股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於二 零二五年四月二十五日（星期五）舉行董事會會議，藉以（其中包括）審議及通過本 公司及其附屬公司截至二零二五年三月三十一日止三個月之第一季度業績及其發 佈。 承董事會命 上海昊海生物科技股份有限公司 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執行 董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | A 股（上海證券交易所科創板，股份代號：688366） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註 ...